3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
4
Prostatic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
SCLC,Extensive Stage
1
Prostatic Neoplasms, Castration-Resistant
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metastatic Castration-sensitive Prostate Cancer
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Interventions
Nuclear Medicine Department, Hospital
6
Magnetic Resonance Spectroscopy
6
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Biopsy
5
Temozolomide
4
Irinotecan
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dinutuximab
2
Cyclophosphamide
2
trametinib
1
tazemetostat
1
talazoparib
1
saponin QA-21V1
1
palbociclib
1
lutetium Lu 177 dotatate
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
dabrafenib
1
Vincristine
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroblastoma
×
niraparib
×
30 days
×
Clear all
No trials found.